Ryan White Program

;

Comments to Sen. Cassidy on 340B Drug Pricing Integrity and Affordability for Patients Act discussion draft

Aug 28, 2026

We submitted comments on the 340B for Patients Act discussion draft, supporting legislative efforts to put the 340B Program on a firm statutory basis so that it can continue to serve people affected by HIV and other serious conditions far into the future. We urge Congress to protect HIV, STD, and other safety-net providers as well as ADAPs, and oppose provisions that would restrict subgrantee eligibility for STD clinics. We support an updated patient definition that does not restrict telemedicine or rapid start interventions. We also strongly support new transparency, reporting, and affordability requirements for hospitals, which account for the vast majority of 340B spending and growth but face no requirements to demonstrate patient benefit.

read more

House testimony on FY27 funding for domestic HIV and hepatitis programs

Apr 16, 2026

The HIV+Hepatitis Policy Institute respectfully submits this testimony in support of increased funding for domestic HIV and hepatitis programs at the Department of Health and Human Services for FY 2027. Specifically, this testimony is in support of funding for the following initiatives, programs and divisions: Ending the HIV Epidemic Initiative – $395 million for the CDC Division of HIV/AIDS Prevention, $358.6 million for the HRSA Ryan White HIV/AIDS Program, $207.3 million for the HRSA Community Health Centers, and $52 million for the Indian Health Service; Ryan White HIV/AIDS Program – $3.13 billion; CDC Division of HIV Prevention – $822.7 million; CDC Division of Viral Hepatitis – $150 million; and the HHS Office of Infectious Disease and HIV/AIDS Policy – $7.6 million.  We also support maintaining funding for CDC’s Eliminating Opioid-Related Infectious Diseases Program and Division of Adolescent and School Health; the Minority HIV/AIDS Initiative; AIDS Research at the NIH; the Title X Family Planning Program; the Teen Pregnancy Prevention Program; and the SAMHSA Hepatitis C Elimination Initiative Pilot.

read more

Support for improving Ryan White HIV/AIDS Program Part A and B formula awards

Dec 8, 2025

We are in strong support of HAB’s proposal included in the Federal Register on November 10, 2025, to update the funding formulas used by the Ryan White HIV/AIDS Program (RWHAP) for allocating Part A and Part B funding. This welcome change is long overdue and will increase equity in the distribution of funding and better match the level of funding with the number of RWHAP clients residing in a jurisdiction.

read more

Senate testimony on FY26 appropriations for HIV and hepatitis

Jun 13, 2025

As a nation, we are able to advance efforts to end the HIV and viral hepatitis epidemics. We possess proven prevention tools, including pre-exposure prophylaxis medication (PrEP), and effective treatments. We urge you to continue your historically strong commitment and leverage this pivotal moment to support the nation’s public health by comprehensively addressing these chronic diseases. Increased investment – and certainly not cuts – in surveillance, education, prevention, and care and treatment will lead to further progress in reducing HIV and viral hepatitis and allow us to continue to hold the promise of ending these epidemics.

read more

House testimony on FY26 appropriations for HIV and hepatitis programs

Apr 9, 2025

This testimony is in support of funding for the following initiatives, programs and divisions at the Department of Health and Human Services: Ending the HIV Epidemic Initiative—$395 million for the CDC Division of HIV/AIDS Prevention, $358.6 million for the HRSA Ryan White HIV/AIDS Program, $207.3 million for the HRSA Community Health Centers, and $52 million for the Indian Health Service; Ryan White HIV/AIDS Program—$3.024 billion; CDC Division of HIV Prevention—$822.7 million; CDC Division of Viral Hepatitis—$150 million; and the HHS Office of Infectious Disease and HIV/AIDS Policy—$20 million. The HIV+Hepatitis Policy Institute also supports maintaining and funding CDC’s Eliminating Opioid-Related Infectious Diseases Program and Division of School and Adolescent Health; the Minority HIV/AIDS Initiative; AIDS Research 2 at the NIH; the Title X Family Planning Program; the Teen Pregnancy Prevention Program; and the SAMHSA HIV Block Grant.

read more

Search

Categories

Tags

340B ACA Appropriations Biden administration CDC CMS co-pay accumulators Congress copay accumulator Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing essential health benefits FDA Gay men Hepatitis Hepatitis B hepatitis C Hepatitis Prevention HHS HIV HIV Prevention Insurers Medicaid medicare Medicare Part D NAIC NIH PBM PBMs PrEP Prescription Drugs prior authorization Private Insurance private insurers Ryan White Program state STDs Syringe services Testing transparency Treatment Trump administration

Recent Testimony, Letters, Comments

Pin It on Pinterest